Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00455260
Status:
COMPLETED
Last Update Posted:
2013-09-02
First Post:
2007-04-02
Brief Title:
A Multi-Dose Study to Assess Tolerability Safety and Pharmacology of hGH-ViaDerm System in Adults With GH-Deficiency
Sponsor:
Teva Neuroscience Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multi-Center Randomized Double-Blind Placebo-Controlled Multiple Dose Study to Assess Tolerability Safety Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm System in Adult Subjects With Growth Hormone Deficiency
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to examine the safety tolerability and pharmacokinetics of transdermal delivery of human Growth Hormone hGH or somatropin using the ViaDerm device in adult patients with Growth Hormone Deficiency Syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None